
Pharmacy student coming back to this one. NO SEMAGLUTIDE. end of story, will destroy everything you’ve worked towards. Tirzepatide is risky, and you’ll lose some. Reta looks promising, but not enough clinical data to see either way to be completely honest. In my opinion? Don’t. Maybe reta one day, but not today.
Okay I just wanted to make sure that’s what you are talking about. This isn’t a GLP-3 however I can see how you think that. GLP-1 is glucagon-like-peptide one, so when someone says a GLP-1 drug, they mean that it is acting as an agonist the receptors that bind to the glucagon like receptor. Double and triple agonists still work on the GLP-1 pathway and mechanism, just attacking it from different areas and utilizing different parts of the pathway and different receptors